Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

PRME Prime Medicine, Inc. Common Stock
$3.33 -0.30% -0.01
Notify me if price changes either direction
Interactive Brokers Logotype

Buy PRME stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 599.3M
Enterprise value 492.6M
Trailing PE -2.0121211716623
Forward PE -3.6863494
PEG Ratio 0.073777776294284
Enterprise to EBITDA -2.503
Enterprise to revenue 82.418
Price to book MRQ 3.628415
Price to sales TTM 100.266914

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 6.0M
EBITDA -196802000
Diluted EPS TTM -1.42
Total Cash (MRQ) 213.3M
Current ratio (MRQ) 6.608
Operating Cash Flow (TTM) -109063000

PRME trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent PRME News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.